Mallinckrodt (MNKKQ)

OTC Markets
0.09
0.00(-4.49%)
After Hours
0.08
-0.01(-15.56%)
- Real-time Data
  • Volume:
    208,350
  • Bid/Ask:
    0.00/0.00
  • Day's Range:
    0.08 - 0.09

MNKKQ Overview

Prev. Close
0.09
Day's Range
0.08-0.09
Revenue
2.14B
Open
0.08
52 wk Range
0.05-0.59
EPS
-8.26
Volume
208,350
Market Cap
6.44M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
255,088
P/E Ratio
-
Beta
2.73
1-Year Change
-75.68%
Shares Outstanding
84,782,926
Next Earnings Date
Aug 09, 2022
What is your sentiment on Mallinckrodt?
or
Market is currently closed. Voting is open during market hours.

Mallinckrodt News

Mallinckrodt Analysis

Mallinckrodt Company Profile

Mallinckrodt Company Profile

Employees
2789

Mallinckrodt plc develops, manufactures, markets, and distributes specialty pharmaceutical products and therapies in the United States, Europe, the Middle East, Africa, and internationally. It operates in two segments, Specialty Brands and Specialty Generics. The company markets branded pharmaceutical products for autoimmune and rare diseases in the areas of neurology, rheumatology, nephrology, ophthalmology, pulmonology, and oncology; immunotherapy and neonatal respiratory critical care therapies; analgesics; cultured skin substitutes; and gastrointestinal products. It offers Acthar Gel, a repository corticotropin injection for rheumatoid arthritis, infantile spasms, systemic lupus erythematosus, multiple sclerosis, systemic dermatomyositis, symptomatic sarcoidosis, severe acute and chronic allergic, and inflammatory diseases; INOmax, a vasodilator to enhance oxygenation and reduce the need for extracorporeal membrane oxygenation; Therakos photopheresis, an immunotherapy treatment platform; Amitiza for constipation; and StrataGraft for the treatment of adults with deep partial-thickness burns. The company is also developing Terlipressin for the treatment of hepatorenal syndrome; and SLN 501 is a ribonucleic acid silencing therap. In addition, it provides specialty generic drugs and active pharmaceutical ingredients. The company markets its branded products to physicians, respiratory therapists, pharmacists, pharmacy buyers, hospital procurement departments, ambulatory surgical centers, and specialty pharmacies. Mallinckrodt plc has collaboration with Silence Therapeutics plc to develop and commercialize ribonucleic acid interference drug targets. The company was founded in 1867 and is based in Dublin, Ireland. On October 12, 2020, Mallinckrodt plc, along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyStrong BuyStrong SellNeutralStrong Sell
Technical IndicatorsBuyNeutralStrong SellBuyStrong Sell
SummaryStrong BuyBuyStrong SellNeutralStrong Sell
  • Return to NYSE soon.
    0
    • Judge John Dorsey issued an oral ruling sustaining the Mallinckrodt debtors’ objections to the administrative Acthar antitrust and RICO claims of Humana and Attestor this morning, ending a months-long dispute that threatened to derail the debtors’ reorganization. Full analysis here: https://reorg.com/mallinckrodt-confirmation-phase-2/
      0
      • What about you, johns, why so afraid to buy more? Coz you are all cuckolds and school boys?
        0
        • I gave you a like)))
          0
        • im scared 😨
          0
      • Good morning! target new 15.70$
        1
        • why mnkkq charge 50 $ tomorrow ?
          0
          • why mnkkq charge 50 $ tomorrow ?
            0
            • Check NMTR, it has a lead medication called larazotide currently at phase 111 clinical trial for celiac disease with the potential of using it to reduce covid-induced respiratory symptoms! Buy and enjoy later analyst consensus price target at $6 but currently trading in pre market at $1.9
              3
              • What happened here? Any news?
                0
                • chapter 11
                  3
                  • https://finance.yahoo.com/news/buxton-helmsley-group-announces-sufficient-200200706.html
                    0
                    • is this news good or Bad for this stock?
                      0
                    • it gives a hope
                      0